Stay updated on Omalizumab in Multi-Allergen OIT Clinical Trial

Sign up to get notified when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Omalizumab in Multi-Allergen OIT Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added a Locations section listing study sites by state (Arkansas, California, Colorado, Georgia, Maryland, Massachusetts, New York, North Carolina, Pennsylvania, Texas) and updated the revision to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-24T15:26:59.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    Publication section updated: added language that publications are provided voluntarily by the person entering information, and the revision label updated to v3.3.2 (replacing the previous phrasing about the study results). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T14:53:32.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Notice about lapse in government funding and operating status has been removed; the page no longer provides guidance to check current status on cc.nih.gov or opm.gov.
    Difference
    0.2%
    Check dated 2025-11-18T07:34:10.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Two screenshots show no substantive changes to the Study Details page; core data remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-27T21:07:23.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Major update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.
    Difference
    0.5%
    Check dated 2025-10-06T08:24:01.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    - Removed multiple MedlinePlus topics: Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, and Substandard Drugs. - Added a new Revision tag: v3.1.0. Overall, core topic coverage is reduced with a version update.
    Difference
    0.1%
    Check dated 2025-09-29T04:57:25.000Z thumbnail image

Stay in the know with updates to Omalizumab in Multi-Allergen OIT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.